Skip to main content
Clinical Trials/NL-OMON35531
NL-OMON35531CompletedNot Applicable

A single-site, open-label study in healthy male subjects to compare rotigotine saliva and plasma concentrations in steady-state after multiple-dose application of rotigotine transdermal patch - Rotigotine transdermal patch study

CB Pharma0 sites14 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
14

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • male; 18 - 25 years; BMI 19.0 - 28.0 kg/m2; no smoking; white skin.

Exclusion Criteria

  • Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 3 months the screening for the study or being a blood donor within 3 months prior to the screening for the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Investigators

Sponsor
CB Pharma

Similar Trials